title: [Severe-grade tetanus in a multipurpose ICU: review of 13 cases].
abstract: BACKGROUND
  The mortality of severe tetanus (grades II-III) remains high today, being greater than 20% with a large number of complications, due to the lengthy stay of these patients in the ICU.
  
  
  METHODS
  A review of 13 cases of severe tetanus over the last 5 years was performed analyzing age, entrance, previous immunization, ICU stay, grade of severity, complications and mortality.
  
  
  RESULTS
  The ages ranged between 35 to 79 years (mean 54 years). No patient had been previously immunized. Entrance was determined in 11 patients (84.6%). The mean ICU stay was 27.3 days. Complications were presented in 76.8% of the patients, with the most frequent being vegetative alterations (38%). The global mortality was 30.7% (4 patient), 3 secondary to sepsis of pulmonary origin and one from a cardiac arrest of vegetative etiology.
  
  
  CONCLUSIONS
  The authors believe that prophylaxis is fundamental in prevention of the disease but an important sector of the population remains unvaccinated. On appearance of severe tetanus, admission to the ICU is essential since many complications may appear requiring specialized techniques and personnel.
authors.affiliation: Servicio de Medicina Intensiva, Hospital General de Especialídades Ciudad de Jaén.
authors.forename: J A
authors.initials: JA
authors.lastname: Camacho
authors.forename: J M
authors.initials: JM
authors.lastname: Jiménez
authors.forename: A
authors.initials: A
authors.lastname: Díaz
authors.forename: A
authors.initials: A
authors.lastname: Montijano
authors.forename: J L
authors.initials: JL
authors.lastname: Quesada
authors.forename: D
authors.initials: D
authors.lastname: Montiel
mesh_terms: D000151:Acinetobacter Infections / Q000150:complications / Q000401:mortality; D000328:Adult; D000368:Aged; D002423:Cause of Death; D003131:Combined Modality Therapy; D003646:Debridement; D003975:Diazepam / Q000627:therapeutic use; D005260:Female; D006323:Heart Arrest / Q000209:etiology; D006801:Humans; D002534:Hypoxia, Brain / Q000150:complications; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007362:Intensive Care Units / Q000706:statistics & numerical data*; D008297:Male; D008875:Middle Aged; D009125:Muscle Relaxants, Central / Q000627:therapeutic use; D003473:Neuromuscular Nondepolarizing Agents / Q000627:therapeutic use; D010197:Pancuronium / Q000627:therapeutic use; D010406:Penicillins / Q000627:therapeutic use; D026741:Physical Therapy Modalities; D018410:Pneumonia, Bacterial / Q000150:complications; D012189:Retrospective Studies; D018805:Sepsis / Q000209:etiology / Q000401:mortality; D012720:Severity of Illness Index; D013030:Spain / Q000453:epidemiology; D013742:Tetanus / Q000150:complications / Q000453:epidemiology* / Q000628:therapy; D013745:Tetanus Toxoid / Q000627:therapeutic use
chemical_list: D016756:Immunoglobulins, Intravenous; D009125:Muscle Relaxants, Central; D003473:Neuromuscular Nondepolarizing Agents; D010406:Penicillins; D013745:Tetanus Toxoid; D010197:Pancuronium; D003975:Diazepam